Remove tag day-one-biopharmaceuticals
article thumbnail

Drug-resistant epilepsy drug Ontozry backed by NICE

pharmaphorum

It is recommended only if it is used as an add-on treatment, after at least one other add-on treatment has not controlled seizures, and treatment is started in a tertiary epilepsy service. Focal onset seizure is a type of epilepsy in which seizures start in one side of the brain, acconting for around 60% of all epilepsy cases.

Drugs 94
article thumbnail

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Delveinsight

The FDA nods for the Elecsys Anti-SARS-CoV-2 S quantitative antibody test that runs on Roche’s cobas e analyzers, follows its September launch in Europe after receiving a CE mark. In the 97-subject clinical trial, children who got OV101 orally once a day for three months improved by 0.7

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Troy Lionberger, PhD, Senior Vice President, Business Development, Bruker, on: ‘Accelerating functional TCR discovery by phenotyping thousands of live, single T cells in two days’. Ioanna Stamati, PhD, Team Leader, Bioconjugation, Antikor Biopharma, on: ‘Antibody fragment drug-conjugates (FDCs): Analysing novel formats with high DAR’.

article thumbnail

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

Following the completion of the spin-off of the Upjohn Business (4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. Amy Rose 212.733.7410. Source link.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Keeping our patients’ needs first, our global manufacturing facilities are now operating 24 hours, seven days a week, and we have invested approximately $1.6 Free Report.

Drugs 264
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Keeping our patients’ needs first, our global manufacturing facilities are now operating 24 hours, seven days a week, and we have invested approximately $1.6 Free Report.

Drugs 246